ColoRectal Cancer Predicted Risk Online (CRC-PRO) Calculator Using Data from the Multi-Ethnic Cohort Study

References

1. 1.↵
   1. Zauber AG,
   2. Lansdorp-Vogelaar I,
   3. Knudsen AB,
   4. Wilschut J,
   5. van Ballegooijen M,
   6. Kuntz KM

   . Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149:659–69.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Levin B,
   2. Lieberman DA,
   3. McFarland B,
   4. et al

   . Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008;58:130–60.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Basow DS

   1. Ahnen DJ,
   2. Macrae FA

   . Colorectal cancer: Epidemiology, risk factors, and protective factors. In: Basow DS, ed. UpToDate. Version 41.0. Waltham, MA; UpToDate; 2013.
4. 4.↵
   1. Sinha R,
   2. Chow WH,
   3. Kulldorff M,
   4. et al

   . Well-done, grilled red meat increases the risk of colorectal adenomas. Cancer Res 1999;59:4320–4.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Hu FB,
   2. Manson JE,
   3. Liu S,
   4. et al

   . Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 1999;91:542–7.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Larsson SC,
   2. Orsini N,
   3. Wolk A

   . Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005;97:1679–87.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Larsson SC,
   2. Giovannucci E,
   3. Wolk A

   . Diabetes and colorectal cancer incidence in the cohort of Swedish men. Diabetes Care 2005;28:1805–7.

   OpenUrlFREE Full Text
8. 8.↵
   1. Alberts DS,
   2. Martinez ME,
   3. Roe DJ,
   4. et al

   . Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. N Engl J Med 2000;342:1156–62.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Bjelakovic G,
   2. Nagorni A,
   3. Nikolova D,
   4. Simonetti RG,
   5. Bjelakovic M,
   6. Gluud C

   . Meta-analysis: antioxidant supplements for primary and secondary prevention of colorectal adenoma. Aliment Pharmacol Ther 2006;24:281–91.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Wactawski-Wende J,
    2. Kotchen JM,
    3. Anderson GL,
    4. et al

    . Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006;354:684–96.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    1. Giovannucci E

    . Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr 2007;86:s836–42.

    OpenUrlPubMed
12. 12.↵
    1. Pischon T,
    2. Lahmann PH,
    3. Boeing H,
    4. et al

    . Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2006;98:920–31.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Freedman AN,
    2. Slattery ML,
    3. Ballard-Barbash R,
    4. et al

    . Colorectal cancer risk prediction tool for white men and women without known susceptibility. J Clin Oncol 2009;27:686–93.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Colditz GA,
    2. Atwood KA,
    3. Emmons K,
    4. et al

    . Harvard report on cancer prevention volume 4: Harvard Cancer Risk Index. Risk Index Working Group, Harvard Center for Cancer Prevention. Cancer Causes Control 2000;11:477–88.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    1. Park Y,
    2. Freedman AN,
    3. Gail MH,
    4. et al

    . Validation of a colorectal cancer risk prediction model among white patients age 50 years and older. J Clin Oncol 2009;27:694–8.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Coughlin SS

    . Recall bias in epidemiologic studies. J Clin Epidemiol 1990;43:87–91.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    1. Goodwin JS,
    2. Singh A,
    3. Reddy N,
    4. Riall TS,
    5. Kuo YF

    . Overuse of screening colonoscopy in the Medicare population. Arch Intern Med 2011;171:1335–43.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    1. Ladabaum U,
    2. Chopra CL,
    3. Huang G,
    4. Scheiman JM,
    5. Chernew ME,
    6. Fendrick AM

    . Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Ann Intern Med 2001;135:769–81.

    OpenUrlPubMedWeb of Science
19. 19.↵
    1. Ladabaum U,
    2. Scheiman JM,
    3. Fendrick AM

    . Potential effect of cyclooxygenase-2-specific inhibitors on the prevention of colorectal cancer: a cost-effectiveness analysis. Am J Med 2003;114:546–54.

    OpenUrlPubMed
20. 20.↵
    1. Meyskens FL Jr.,
    2. McLaren CE,
    3. Pelot D,
    4. et al

    . Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila Pa) 2008;1:32–8.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Kolonel LN,
    2. Henderson BE,
    3. Hankin JH,
    4. et al

    . A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol 2000;151:346–57.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    1. Freedman AN,
    2. Seminara D,
    3. Gail MH,
    4. et al

    . Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst 2005;97:715–23.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Durrleman S,
    2. Simon R

    . Flexible regression models with cubic splines. Stat Med 1989;8:551–61.

    OpenUrlCrossRefPubMedWeb of Science
24. 24.↵
    1. Royston P,
    2. Altman DG,
    3. Sauerbrei W

    . Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 2006;25:127–41.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. Kattan MW,
    2. Zelefsky MJ,
    3. Kupelian PA,
    4. Scardino PT,
    5. Fuks Z,
    6. Leibel SA

    . Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000;18:3352–9.

    OpenUrlAbstract/FREE Full Text
26. 26.↵
    1. Harrell FE Jr.,
    2. Lee KL,
    3. Mark DB

    . Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361–87.

    OpenUrlCrossRefPubMedWeb of Science
27. 27.↵
    1. Van Burren S,
    2. Oudshoorn CGM

    . MICE: multivariate imputation by chained equations. R package version 2.3. Available from: http://www.stefvanbuuren.nl/mi/MICE.html. Accessed November 16, 2013.
28. 28.↵
    1. Harrell FE Jr.,
    2. Califf RM,
    3. Pryor DB,
    4. Lee KL,
    5. Rosati RA

    . Evaluating the yield of medical tests. JAMA 1982;247:2543–6.

    OpenUrlCrossRefPubMedWeb of Science
29. 29.↵
    1. Wells BJ,
    2. Yu C,
    3. Koroukian S,
    4. Kattan MW

    . Comparison of variable selection methods for the generation of parsimonious prediction models for use in clinical practice. Presented at the 33rd Annual Meeting of the Society for Medical Decision Making. Available from: http://smdm.confex.com/smdm/2011ch/webprogram/Paper6541.html. Accessed December 10, 2012.
30. 30.↵
    1. Statements P

    . Standards of medical care in diabetes—2012. Diabetes Care 2012;35(Suppl 1):S11–63.

    OpenUrlFREE Full Text
31. 31.↵
    Surveillance, Epidemiology, and End Results Program. Fast stats: an interactive tool for access to SEER cancer statistics. Washington, DC: National Cancer Institute. Available from: http://seer.cancer.gov/faststats. Accessed November 19, 2013.
32. 32.↵
    1. Loftus EV Jr.

    . Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504–17.

    OpenUrlCrossRefPubMedWeb of Science
33. 33.↵
    1. Itzkowitz SH,
    2. Present DH

    ; Crohn's and Colitis Foundation of America Colon Cancer in IBD Study Group. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:314–21.

    OpenUrlCrossRefPubMedWeb of Science
34. 34.↵
    1. Ness RM,
    2. Holmes AM,
    3. Klein R,
    4. Dittus R

    . Cost-utility of one-time colonoscopic screening for colorectal cancer at various ages. Am J Gastroenterol 2000;95:1800–11.

    OpenUrlCrossRefPubMedWeb of Science
35. 35.↵
    1. Eaden JA,
    2. Abrams KR,
    3. Mayberry JF

    . The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526–35.

    OpenUrlAbstract/FREE Full Text
36. 36.↵
    1. Asano TK,
    2. McLeod RS

    . Non steroidal anti-inflammatory drugs (NSAID) and aspirin for preventing colorectal adenomas and carcinomas. Cochrane Database Syst Rev 2004;(2):CD004079.
37. 37.↵
    1. Flossmann E,
    2. Rothwell PM

    ; British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007;369:1603–13.

    OpenUrlCrossRefPubMedWeb of Science
38. 38.↵
    1. Rostom A,
    2. Dubé C,
    3. Lewin G,
    4. et al

    . Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007;146:376–89.

    OpenUrlCrossRefPubMedWeb of Science
39. 39.↵
    1. Loprinzi CL,
    2. Messing EM,
    3. O'Fallon JR,
    4. et al

    . Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials. Cancer Epidemiol Biomarkers Prev 1996;5:371–4.

    OpenUrlAbstract/FREE Full Text
40. 40.↵
    1. Meyskens FL Jr.,
    2. Emerson SS,
    3. Pelot D,
    4. et al

    . Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps. J Natl Cancer Inst 1994;86:1122–30.

    OpenUrlAbstract/FREE Full Text
41. 41.↵
    1. Meyskens FL Jr.,
    2. Gerner EW,
    3. Emerson S,
    4. et al

    . Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. J Natl Cancer Inst 1998;90:1212–8.

    OpenUrlAbstract/FREE Full Text